Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PROK Stock Forecast 2025-2026
$0.81
Current Price
$1.81B
Market Cap
Buy 4
Hold 3
Sell 0
Wall St Analyst Ratings
Distance to PROK Price Targets
+641.1%
To High Target of $6.00
+517.6%
To Median Target of $5.00
+270.6%
To Low Target of $3.00
PROK Price Momentum
+12.5%
1 Week Change
+2.5%
1 Month Change
-80.0%
1 Year Change
-52.1%
Year-to-Date Change
-81.8%
From 52W High of $4.44
+76.0%
From 52W Low of $0.46
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching ProKidney (PROK) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on PROK and similar high-potential opportunities.
Latest PROK Stock Price Targets & Analyst Predictions
Based on our analysis of 10 Wall Street analysts, PROK has a bullish consensus with a median price target of $5.00 (ranging from $3.00 to $6.00). The overall analyst rating is Strong Buy (8.3/10). Currently trading at $0.81, the median forecast implies a 517.6% upside. This outlook is supported by 4 Buy, 3 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Vamil Divan at Guggenheim, projecting a 641.1% upside. Conversely, the most conservative target is provided by Jason Gerberry at B of A Securities, suggesting a 270.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PROK Analyst Ratings
4
Buy
3
Hold
0
Sell
PROK Price Target Range
Low
$3.00
Average
$5.00
High
$6.00
Current: $0.81
Latest PROK Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PROK.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Sep 30, 2024 | JP Morgan | Anupam Rama | Neutral | Initiates | $0.00 |
| Sep 10, 2024 | Guggenheim | Vamil Divan | Buy | Initiates | $6.00 |
| Sep 4, 2024 | B of A Securities | Jason Gerberry | Neutral | Maintains | $3.00 |
| Jun 10, 2024 | Jefferies | Kelly Shi | Buy | Maintains | $6.00 |
| May 29, 2024 | B of A Securities | Jason Gerberry | Neutral | Maintains | $4.00 |
| Mar 7, 2024 | Morgan Stanley | Judah Frommer | Equal-Weight | Assumes | $3.00 |
| Jan 2, 2024 | B of A Securities | Jason Gerberry | Neutral | Downgrade | $2.00 |
| Jul 25, 2023 | BTIG | Justin Zelin | Buy | Initiates | $16.00 |
| Dec 21, 2022 | Jefferies | Kelly Shi | Buy | Initiates | $15.00 |
| Nov 10, 2022 | Morgan Stanley | Vikram Purohit | Equal-Weight | Initiates | $13.00 |
| Oct 18, 2022 | UBS | Colin Bristow | Buy | Initiates | $18.00 |
| Oct 14, 2022 | Citigroup | Yigal Nochomovitz | Buy | Initiates | $16.00 |
| Sep 2, 2022 | Evercore ISI Group | Jonathan Miller | Outperform | Initiates | $0.00 |
ProKidney Corp (PROK) Competitors
The following stocks are similar to ProKidney based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ProKidney Corp (PROK) Financial Data
ProKidney Corp has a market capitalization of $1.81B with a P/E ratio of -1.3x. The company generates $306,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +202.6% quarter-over-quarter, while maintaining an operating margin of -17,994.8% and return on equity of -45.3%.
Valuation Metrics
Market Cap
$1.81B
Enterprise Value
$1.15B
P/E Ratio
-1.3x
PEG Ratio
-1.6x
Price/Sales
5,921.0x
Growth & Margins
Revenue Growth (YoY)
+202.6%
Gross Margin
N/A
Operating Margin
-17,994.8%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+313.2%
Current Ratio
11.0x
Debt/Equity
0.9x
ROE
-45.3%
ROA
-28.3%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
ProKidney Corp (PROK) Business Model
About ProKidney Corp
What They Do
Developing cell therapies for chronic kidney disease.
Business Model
ProKidney Corp generates revenue by developing and commercializing innovative regenerative therapies for chronic kidney disease (CKD), primarily through its flagship product, REACT, an autologous cell therapy. The company collaborates with healthcare institutions and research organizations to conduct clinical trials, aiming to bring its therapies to market and improve patient outcomes.
Additional Information
As CKD represents a significant global health issue, ProKidney's advancements could lead to reduced reliance on dialysis and kidney transplants, addressing a critical need in healthcare. The company's position in the biotechnology sector and its focus on cutting-edge solutions place it at the forefront of medical technology advancements.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
204
CEO
Dr. Bruce Culleton M.D.
Country
United States
IPO Year
2022
Website
prokidney.comProKidney Corp (PROK) Latest News & Analysis
Latest News
Quick Summary
ProKidney Corp. (Nasdaq: PROK) reported its Q1 2025 financial results and business highlights, focusing on its late-stage therapies for chronic kidney disease.
Why It Matters
ProKidney's quarterly financial results indicate its performance and growth potential in the CKD market, impacting stock valuation and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
PROKIDNEY CP (PROK) is technically oversold, suggesting reduced selling pressure. Analysts are raising earnings estimates, indicating a potential stock trend reversal.
Why It Matters
PROKIDNEY CP's oversold status and revised higher earnings estimates suggest a possible rebound in stock price, signaling a favorable entry point for investors.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
ProKidney Corp. (Nasdaq: PROK) reported its financial results and business highlights for 2024, focusing on its late clinical-stage therapies for chronic kidney disease.
Why It Matters
ProKidney's financial results and business highlights indicate its growth trajectory in the cellular therapeutics sector, which can impact its stock performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The health care sector has oversold stocks, indicating potential investment opportunities in undervalued companies.
Why It Matters
Oversold health care stocks may indicate potential for price recovery, presenting buying opportunities for investors seeking undervalued assets in a critical sector.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
Kuehn Law is investigating ProKidney Corp. (NASDAQ: PROK) for possible breaches of fiduciary duty by its officers and directors, focusing on potential self-dealing.
Why It Matters
The investigation into ProKidney Corp.'s officers for potential fiduciary breaches raises concerns about governance and could impact shareholder value and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
ProKidney's Rilparencel aims to stabilize kidneys for CKD patients. Phase 2 data is expected in 2025, with Phase 3 results due by Q3 2027, pending FDA surrogate endpoint confirmation.
Why It Matters
The timeline for Rilparencel's data releases impacts ProKidney's stock prospects, influencing investor sentiment based on potential FDA approval and market readiness for CKD treatments.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About PROK Stock
What is ProKidney Corp's (PROK) stock forecast for 2025?
Based on our analysis of 10 Wall Street analysts, ProKidney Corp (PROK) has a median price target of $5.00. The highest price target is $6.00 and the lowest is $3.00.
Is PROK stock a good investment in 2025?
According to current analyst ratings, PROK has 4 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.81. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PROK stock?
Wall Street analysts predict PROK stock could reach $5.00 in the next 12 months. This represents a 517.6% increase from the current price of $0.81. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is ProKidney Corp's business model?
ProKidney Corp generates revenue by developing and commercializing innovative regenerative therapies for chronic kidney disease (CKD), primarily through its flagship product, REACT, an autologous cell therapy. The company collaborates with healthcare institutions and research organizations to conduct clinical trials, aiming to bring its therapies to market and improve patient outcomes.
What is the highest forecasted price for PROK ProKidney Corp?
The highest price target for PROK is $6.00 from Vamil Divan at Guggenheim, which represents a 641.1% increase from the current price of $0.81.
What is the lowest forecasted price for PROK ProKidney Corp?
The lowest price target for PROK is $3.00 from Jason Gerberry at B of A Securities, which represents a 270.6% increase from the current price of $0.81.
What is the overall PROK consensus from analysts for ProKidney Corp?
The overall analyst consensus for PROK is bullish. Out of 10 Wall Street analysts, 4 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $5.00.
How accurate are PROK stock price projections?
Stock price projections, including those for ProKidney Corp, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 17, 2025 10:54 AM UTC